Browse All

Current Filters

CLEAR FILTER x

TITLE

BHV-2100, a First-in-class TRPM3 Antagonist for the Treatment of Pain

Author:Vriens, Joris   Vanherck, Jean-Christophe   Marchand, Arnaud   Carr, Bruce   Dubowchik, Gene   Caldwell, Reese   Granit, Volkan   Marcin, Lawrence   Pirman, David   Chaltin, Patrick   Voets, Thomas   

Session Name:S13: Pain Research  

Topic:Pain  

Program Number:S13.002  

Author Institution:Laboratory of Ion Channel Research, Leuven, Belgium  CISTIM Leuven vzw, Leuven, Belgium  Biohaven Pharmaceuticals, Inc, New Haven, CT  CISTIM Leuven vzw and Centre for Drug Design and Discovery (CD3), Leuven, Belgium  Laboratory of Ion Channel Research and VIB Center for Brain & Disease Research, Leuven, Belgium  

Novel Bispecific Degrader BHV-1300 Achieves Rapid, Robust, and Selective IgG Reduction in Preclinical Models Including Nonhuman Primates

Author:Bunin, Anna   Lee, Seong   Kazmierski, Wes   McGrath, Kathleen   Rossi, Anne Marie   Nicholson, Simone   Dubowchik, Gene   Dierks, Elizabeth   Sharpe, Neal   Pirman, David   Car, Bruce   Qureshi, Irfan   Coric, Vladimir   Spiegel, David   

Session Name:S43: Advances in General Neurology  

Topic:General Neurology  

Program Number:S43.004  

Author Institution:Biohaven Pharmaceuticals, Inc, New Haven, CT  Yale University, New Haven, CT